Tesaglitazar AstraZeneca.

Tim, Davis

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2003

Data sources: Europe PubMed Central

Tesaglitazar AstraZeneca.

descriptionPublicationkeyboard_double_arrow_right Article 22 Dec 2003 English Journal:IDrugs : the investigational drugs journal, volume 5 (issn: 1369-7056,

Copyright policy )

Authors: Tim, Davis;

pmid: 12800054

Tesaglitazar AstraZeneca.

- Summary
- Metrics

Abstract

AstraZeneca (formerly Astra) is developing tesaglitazar, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of diabetes and insulin resistance [275466], [377656]. Early phase clinical trials for both of these indications were ongoing in July 2002 [459440].

Related Organizations

University of Western Australia
Australia
Fremantle Hospital
Australia

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average